GlassScriptPhysician profile
Lisa M Harris
NPI 1609395110
$8,724.82
in general payments reported to CMS, 2019-2025
20 companies · $2,688 in 2025
The $2,688 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $1,131 · 2023: $1,551 · 2024: $3,147 · 2025: $2,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,378 · Education: $7.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,378.15 |
| Education | $7.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,100.07 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $902.75 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $879.15 | 2022-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $838.62 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $812.27 | 2022-2025 | Quviviq, Quviviq |
| Otsuka America Pharmaceutical, INC. | $771.48 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $565.56 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $307.44 | 2024-2025 | Qelbree |
| Lundbeck LLC | $259.61 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $227.98 | 2024-2025 | Airsupra, Breztri |
| Axsome Therapeutics, INC. | $207.25 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $195.42 | 2022-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $177.06 | 2021-2025 | Lybalvi, Aristada |
| Tris Pharma INC | $133.56 | 2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Lilly USA, LLC | $125.00 | 2025 | Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $102.91 | 2023-2025 | Wegovy, Ozempic |
| Indivior INC. | $47.07 | 2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $40.22 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $15.79 | 2024 | |
| Bausch Health US, LLC | $15.61 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.